Akari Therapeutics (AKTX) Income from Continuing Operations (2014 - 2026)
Akari Therapeutics recorded quarterly Income from Continuing Operations of 14455000.0 in Q1 2026, down 172.84% quarter-over-quarter from 5298000.0 in Q4 2025, and down 290.15% year-over-year from 7601955.29 in Q1 2025.
Akari Therapeutics' Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 14455000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 290.15% year-over-year to 14455000.0; the TTM figure through Mar 2026 stood at 29322000.0 (down 64.09% YoY), while the FY2025 annual figure was 17298000.0, up 12.6% from the prior year.
- Income from Continuing Operations came in at 14455000.0 for Q1 2026 at Akari Therapeutics, down from 5298000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2491000.0 in Q3 2023 to a low of 14455000.0 in Q1 2026.
- A 5-year average of 5396988.0 and a median of 5083000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations jumped 57.74% in 2025 and tumbled 290.15% in 2026, its largest moves.
- Akari Therapeutics' Income from Continuing Operations stood at 5812197.0 in 2022, then advanced by 12.55% to 5083000.0 in 2023, then climbed by 25.79% to 3772000.0 in 2024, then sank by 40.46% to 5298000.0 in 2025, then slumped by 172.84% to 14455000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 14455000.0, 5298000.0, and 6400000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -453.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.46 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Sep 30, 2025 | -6.40 Mn |
| Jun 30, 2025 | -3.17 Mn |
| Mar 31, 2025 | -3.58 Mn |
| Dec 31, 2024 | -3.77 Mn |
| Sep 30, 2024 | -2.90 Mn |
| Jun 30, 2024 | -7.50 Mn |
| Mar 31, 2024 | -5.99 Mn |
| Dec 31, 2023 | -5.08 Mn |
| Sep 30, 2023 | -2.49 Mn |
| Jun 30, 2023 | -4.59 Mn |
| Mar 31, 2023 | -4.56 Mn |
| Jun 30, 2022 | -5.81 Mn |
| Mar 31, 2022 | -5.24 Mn |
| Dec 31, 2021 | -20.46 Bn |
| Sep 30, 2021 | -1.46 Mn |
| Jun 30, 2021 | -4.33 Mn |
| Mar 31, 2021 | -5.54 Mn |
| Dec 31, 2020 | -6.89 Mn |
| Sep 30, 2020 | -240,751.00 |
| Jun 30, 2020 | -5.91 Mn |
| Mar 31, 2020 | -4.93 Mn |
| Dec 31, 2019 | -7.82 Mn |
| Sep 30, 2019 | -3.12 Mn |
| Jun 30, 2019 | -6.03 Mn |
| Mar 31, 2019 | 13,248.00 |
| Dec 31, 2018 | -4.71 Mn |
| Sep 30, 2018 | -2.92 Mn |
| Jun 30, 2018 | -7.91 Mn |
| Mar 31, 2018 | -4.24 Mn |
| Dec 31, 2017 | -13.56 Mn |
| Sep 30, 2017 | -8.49 Mn |
| Jun 30, 2017 | -7.31 Mn |
| Mar 31, 2017 | -8.24 Mn |
| Dec 31, 2016 | 10.98 Mn |
| Sep 30, 2016 | -1.57 Mn |
| Jun 30, 2016 | -7.50 Mn |
| Mar 31, 2016 | -2.99 Mn |
| Dec 31, 2015 | 51.76 Mn |
| Sep 30, 2015 | -48.74 Mn |
| Jun 30, 2015 | -1.67 Mn |
| Mar 31, 2015 | -1.70 Mn |
| Dec 31, 2014 | -1.11 Mn |
| Sep 30, 2014 | -223,129.00 |
| Jun 30, 2014 | -2.23 Mn |
| Mar 31, 2014 | -1.74 Mn |